Cilengitide
An integrin-blocking peptide that failed in glioblastoma
Cilengitide is an arginine-glycine-aspartic acid (RGD) peptide that blocks alphavbeta3 and alphavbeta5 integrins, which help tumours grow blood vessels and invade. Promising early trials in glioblastoma led to the phase 3 CENTRIC trial, where median survival was 26.3 months with and without it.
Used in human trials: 2,000 mg, Twice weekly, Intravenous (Trial: CENTRIC (methylated MGMT glioblastoma)) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Integrins alphavbeta3 and alphavbeta5 regulate angiogenesis and invasiveness in cancer, and cilengitide was designed as an integrin-targeting arginine-glycine-aspartic acid (RGD) peptide to block them. In preclinical glioblastoma models it was active and worked with radiotherapy, and early clinical trials found it well tolerated with signs of activity, which led to a planned phase 3 trial.
In recurrent glioblastoma, a randomised phase 2 trial of 81 patients found an excellent safety profile and more activity at the higher dose (6-month progression-free survival 15%, median survival 9.9 months). In newly diagnosed disease, a phase 2 trial in patients without MGMT promoter methylation reported median survival of 16.3 months with the standard cilengitide regimen against 13.4 months for controls.
The decisive test was CENTRIC: 545 patients with methylated MGMT promoter tumours were randomised to standard treatment with or without cilengitide. Median overall survival was 26.3 months in both groups (hazard ratio 1.02), and no subgroup benefited. Later biomarker work confirmed that both CENTRIC and CORE missed their primary endpoints. Cilengitide was not approved.
Later work found the same pattern of near misses: a phase II combination in unmethylated glioblastoma fell short of its survival target, and a re-read of CENTRIC scans showed cilengitide more often caused imaging changes that mimicked progression. Outside the brain, CERTO added cilengitide to cetuximab and chemotherapy in advanced lung cancer; progression-free and overall survival leaned its way but missed significance.
Pharmacologically it is simple: given intravenously, about four-fifths of the dose leaves unchanged in urine, with no circulating metabolites. Combination phase 1 studies kept the 2,000 mg twice-weekly dose. Single exceptional responses exist, such as a woman in CENTRIC with no recurrence after ten years, and laboratory work keeps proposing who might respond, but in CENTRIC no subgroup benefited.
Mechanism of Action
Cilengitide is an RGD peptide designed to block the alphavbeta3 and alphavbeta5 integrins involved in angiogenesis and tumour invasion.
Integrin blockade
It was designed to block alphavbeta3 and alphavbeta5 integrins by mimicking their arginine-glycine-aspartic acid binding motif.
Angiogenesis
Blocking these integrins was meant to cut tumour blood supply and invasion, which worked in preclinical glioblastoma models.
Simple clearance
It is cleared mainly unchanged in urine, with no circulating metabolites.
Published Research
Studies of cilengitide, from their PubMed abstracts.
CENTRIC phase 3
In 545 patients with MGMT-methylated glioblastoma, median overall survival was 26.3 months with cilengitide and 26.3 months without (hazard ratio 1.02, p = 0.86); no subgroup benefited and no additional toxicity was seen.
CORE: unmethylated tumours
Median overall survival was 16.3 months with standard cilengitide (HR 0.686, p = 0.032) and 14.5 months with intensive cilengitide against 13.4 months for controls; cilengitide was well tolerated.
Recurrent glioblastoma phase 2
In 81 patients, cilengitide had an excellent safety profile; activity trended better at 2,000 mg, with 6-month progression-free survival of 15% and median survival of 9.9 months.
Biomarkers after CENTRIC and CORE
In the two failed phase 3 trials, integrin biomarkers did not predict benefit in CENTRIC; in CORE, higher tumour αvβ3 levels were associated with longer progression-free and overall survival on cilengitide.
With metronomic chemotherapy
In 29 patients with newly diagnosed unmethylated glioblastoma, cilengitide 2,000 mg twice weekly with metronomic temozolomide and procarbazine gave 12-month survival of 55%, short of the 65% target; median survival was 14.5 months.
Scans that mimic progression
Among 424 evaluable CENTRIC patients, treatment-related imaging changes that looked like progression were more common with cilengitide than without (24% against 17%), mostly in the first months after radiotherapy.
Lung cancer with chemoradiotherapy
In a phase I study of 14 patients with stage III non-small-cell lung cancer, continuous cilengitide infusion with chemoradiotherapy produced one dose-limiting toxicity (a tracheobronchial fistula at 40 mg/h); median progression-free survival was 14.4 months, uncontrolled.
Lung cancer with cetuximab (CERTO)
In 169 patients with advanced non-small-cell lung cancer, adding cilengitide to cetuximab and platinum chemotherapy gave progression-free survival of 6.2 against 5.0 months (P = 0.085) and median survival of 13.6 against 9.7 months, not significant; side effects were similar.
With cediranib in recurrent glioblastoma
In 45 patients, cediranib 30 mg daily with cilengitide 2,000 mg twice weekly caused no dose-limiting toxicity, but median survival was 6.5 months and 6-month progression-free survival 4.4%.
With paclitaxel in solid tumours
In a phase 1 study of 12 evaluable patients, cilengitide with weekly paclitaxel was tolerated, with one partial response; the recommended dose was 2,000 mg twice weekly.
How the body clears it
After intravenous radiolabelled cilengitide, about 79% of the dose was excreted in urine, 77.5% unchanged, with no circulating metabolites; two minor metabolites appeared in faeces.
A 10-year survivor
A 77-year-old woman with MGMT-methylated glioblastoma treated in CENTRIC continued cilengitide until 2016 and had no radiographic recurrence more than 10 years after diagnosis.
Ex vivo response in head and neck cancer
An ex vivo assay found only a subgroup of head and neck cancers responded to cilengitide-containing combinations, and that response classified patient outcome.
Why it looked promising
Cilengitide was active and synergised with radiotherapy in preclinical glioblastoma models, showed antitumour benefit with minimal toxicity in recurrent disease, and encouraging single-arm results led to a phase 3 trial.
Integrin levels predict sensitivity
In breast cancer cell lines, high overall integrin levels predicted resistance to cilengitide, while low-integrin luminal lines were all sensitive.
Dosing Data
Never approved. The phase 3 glioblastoma trials gave 2,000 mg intravenously twice weekly with chemoradiotherapy.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form Cilengitide is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Cilengitide is prepared and given by clinical staff, by a cancer team in hospital.
In the carded trials it was infused into a vein alongside radiotherapy and chemotherapy for glioblastoma.
Source: PMID 25163906 and PMID 25762461 (studies carded under Research below).
Storage before and after mixing
Unknown: no label on file says how Cilengitide is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous (Twice weekly; Trial: CENTRIC (methylated MGMT glioblastoma)).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Trial: CENTRIC (methylated MGMT glioblastoma): With temozolomide chemoradiotherapy; Trial: CORE intensive arm (unmethylated MGMT): With chemoradiotherapy and maintenance.
When effects appear: unknown; no source on this page gives a time to effect for Cilengitide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: No additional toxicity over standard treatment in CENTRIC; Lymphopenia and thrombocytopenia occurred in both arms. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Cilengitide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the trials above”).
Interactions
Unknown: a PubMed search for human interaction studies of Cilengitide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Cilengitide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: In Clinical Trials (Not approved anywhere). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the trials above.
Contraindications & Cautions
No label; it is investigational.
Legal Status
Cilengitide is investigational and not approved.
Frequently Asked Questions
?What is cilengitide?
An investigational RGD peptide that blocks alphavbeta3 and alphavbeta5 integrins, developed as a treatment for glioblastoma.
?Why did cilengitide fail?
In the phase 3 CENTRIC trial, median survival was 26.3 months with or without it, and no subgroup benefited, despite encouraging earlier phase 2 results.
?Is cilengitide available?
No. It was never approved, and anything sold under its name is an unverified research chemical.
?Was cilengitide safe?
Yes, in the trials: the recurrent glioblastoma phase 2 study reported no significant reproducible toxicities, and CENTRIC found no overall additional toxic effects over standard treatment; lymphopenia and thrombocytopenia occurred in both arms.
?Did any trial show a survival benefit?
The phase 2 CORE trial in unmethylated tumours reported 16.3 months with the standard cilengitide regimen against 13.4 months for controls, but the trial missed its primary endpoint and the larger CENTRIC trial found no benefit.
?Which patients were in CENTRIC?
Of 3,471 patients screened, 926 had a methylated MGMT promoter and 545 were randomised to standard radiotherapy and temozolomide with or without cilengitide.
?Was cilengitide tried outside glioblastoma?
Yes. In advanced non-small-cell lung cancer, CERTO added it to cetuximab and chemotherapy; survival trends favoured it but were not significant. Phase 1 combinations in other solid tumours showed occasional responses.
?How is cilengitide eliminated?
Mostly unchanged in urine: about 79% of an intravenous dose was recovered in urine and 77.5% as unchanged drug, with no circulating metabolites.
References
- [clinical-trial] Stupp R, et al. "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial." Lancet Oncol, 2014;15(10):1100-8. PMID: 25163906.
- [clinical-trial] Nabors LB, et al. "Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study." Neuro Oncol, 2015;17(5):708-17. PMID: 25762461.
- [clinical-trial] Reardon DA, et al. "Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme." J Clin Oncol, 2008;26(34):5610-7. PMID: 18981465.
- [pubmed] Weller M, et al. "Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome." Oncotarget, 2016;7(12):15018-32. PMID: 26918452.
- [pubmed] Reardon DA, et al. "Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme." Expert Opin Investig Drugs, 2008;17(8):1225-35. PMID: 18616418.
- [clinical-trial] Khasraw M, et al. "Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial." J Neurooncol, 2016;128(1):163-171. PMID: 26935578.
- [pubmed] Flies CM, et al. "Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide." Neuro Oncol, 2024;26(5):902-910. PMID: 38219019.
- [clinical-trial] Massabeau C, et al. "Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study." Clin Lung Cancer, 2018;19(3):e277-e285. PMID: 29221762.
- [pubmed] Vansteenkiste J, et al. "Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)." Ann Oncol, 2015;26(8):1734-40. PMID: 25939894.
- [pubmed] Gerstner ER, et al. "A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma." Neuro Oncol, 2015;17(10):1386-92. PMID: 26008604.
- [pubmed] Haddad T, et al. "A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors." Cancer Chemother Pharmacol, 2017;79(6):1221-1227. PMID: 28477227.
- [pubmed] Becker A, et al. "Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans." J Clin Pharmacol, 2015;55(7):815-24. PMID: 25683324.
- [pubmed] Alalami H, et al. "Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report." CNS Oncol, 2023;12(2):CNS96. PMID: 37092563.
- [pubmed] Cedra S, et al. "Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients." Cancers (Basel), 2017;9(9). PMID: 28872582.
- [pubmed] Girnius N, et al. "Cilengitide sensitivity is predicted by overall integrin expression in breast cancer." Breast Cancer Res, 2024;26(1):187. PMID: 39707454.
- [pubmed] Pan X, et al. "Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model." Bioengineered, 2022;13(2):4557-4572. PMID: 35142593.
Sources & Citations
Studies were read from their PubMed abstracts. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.